Gracell Biotechnologies Inc expected to post a loss of 13 cents a share - Earnings Preview

Gracell Biotechnologies

11/11/2022 17:56

* Gracell Biotechnologies Inc  GRCL.OQ   GRCL.O  is expected
to show a rise in quarterly revenue when it reports  results on
November 14. 
    * The Shanghai-based  company is expected to report revenue
of $25
thousand, according to the mean estimate from 4 analysts, based
on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Gracell
Biotechnologies
Inc is for a loss of 13 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Gracell
Biotechnologies Inc is $15​, above​ its last closing price
of $3.78. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.07       -0.07      -0.30     Missed  -300
 Mar. 31 2022  -0.23       -0.21      -0.35     Missed  -66.7
 Dec. 31 2021  -0.33       -0.33      -0.30     Beat    9.1​
 Sep. 30 2021  -0.15       -0.12      -0.30     Missed  -150
 ​​Jun.        -0.12       -0.12      -0.20     Missed  -71.4
 30 2021                                                
 Mar. 31 2021  -0.21       -0.21      -0.25     Missed  -17.2​
 Dec. 31 2020  -0.26       -0.26      -0.16     Beat    37.5
 This summary was machine generated November 11 at 17:56 GMT. 
All figures in US dollars  unless otherwise stated